(NASDAQ: YMAB) Y Mabs Therapeutics's forecast annual revenue growth rate of 14.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Y Mabs Therapeutics's revenue in 2024 is $84,819,000.On average, 3 Wall Street analysts forecast YMAB's revenue for 2024 to be $4,209,037,314, with the lowest YMAB revenue forecast at $4,178,962,443, and the highest YMAB revenue forecast at $4,244,759,432. On average, 2 Wall Street analysts forecast YMAB's revenue for 2025 to be $4,853,786,517, with the lowest YMAB revenue forecast at $4,853,611,408, and the highest YMAB revenue forecast at $4,854,005,402.
In 2026, YMAB is forecast to generate $5,518,322,971 in revenue, with the lowest revenue forecast at $5,420,962,689 and the highest revenue forecast at $5,615,727,029.